📣 VC round data is live. Check it out!
- Public Comps
- CollPlant
CollPlant Valuation Multiples
Discover revenue and EBITDA valuation multiples for CollPlant and similar public comparables like SpectraCure, Inventionmed, Predict, ScandiDos and more.
CollPlant Overview
About CollPlant
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Founded
1981
HQ

Employees
57
Website
Financials (FY)
EV
$4M
Valuation Multiples
Start free trialCollPlant Financials
CollPlant reported last fiscal year revenue of $2M and negative EBITDA of ($11M).
In the same fiscal year, CollPlant generated $2M in gross profit, ($11M) in EBITDA losses, and had net loss of ($11M).
Revenue (LTM)
CollPlant P&L
In the most recent fiscal year, CollPlant reported revenue of $2M and EBITDA of ($11M).
CollPlant is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (446%), and net margin of (485%).
Financial data powered by Morningstar, Inc.
CollPlant Stock Performance
CollPlant has current market cap of $6M, and enterprise value of $4M.
Market Cap Evolution
CollPlant's stock price is $0.41.
CollPlant share price increased by 2.0% in the last 30 days, and decreased by 69.8% in the last year.
CollPlant has an EPS (earnings per share) of $-0.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4M | $6M | 2.0% | 2.0% | -23.5% | -69.8% | $-0.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCollPlant Valuation Multiples
CollPlant trades at 1.8x EV/Revenue multiple, and (0.4x) EV/EBITDA.
EV / Revenue (LTM)
CollPlant Financial Valuation Multiples
As of June 2, 2026, CollPlant has market cap of $6M and EV of $4M.
CollPlant has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CollPlant Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


CollPlant Margins & Growth Rates
In the most recent fiscal year, CollPlant reported gross margin of 65%, EBITDA margin of (446%), and net margin of (485%).
CollPlant Margins
CollPlant Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
CollPlant Operational KPIs
CollPlant's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
CollPlant Competitors
CollPlant competitors include SpectraCure, Inventionmed, Predict, ScandiDos, Spineway, Lucyd, Steakholder Foods, Qlife Holding, AMA Corp and Vicarious Surgical.
Most CollPlant public comparables operate across Medical Devices, 3D Printing, BioTech, DeepTech, Industry 4.0 and Longevity.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (1.9x) | - | |||
| 8.0x | - | 21.0x | - | |||
| 0.5x | - | 4.4x | - | |||
| 0.8x | - | 20.4x | - | |||
| 0.2x | 0.2x | (3.7x) | (3.4x) | |||
| 0.3x | 0.2x | (0.1x) | (0.1x) | |||
| - | - | (0.5x) | - | |||
| 199.0x | - | (3.5x) | - | |||
This data is available for Pro users. Sign up to see all CollPlant competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CollPlant
| When was CollPlant founded? | CollPlant was founded in 1981. |
| Where is CollPlant headquartered? | CollPlant is headquartered in United States. |
| How many employees does CollPlant have? | As of today, CollPlant has over 57 employees. |
| Who is the CEO of CollPlant? | CollPlant's CEO is Eran Rotem. |
| Is CollPlant publicly listed? | Yes, CollPlant is a public company listed on Nasdaq. |
| What is the stock symbol of CollPlant? | CollPlant trades under CLGN ticker. |
| When did CollPlant go public? | CollPlant went public in 2021. |
| Who are competitors of CollPlant? | CollPlant main competitors include SpectraCure, Inventionmed, Predict, ScandiDos, Spineway, Lucyd, Steakholder Foods, Qlife Holding, AMA Corp, Vicarious Surgical. |
| What is the current market cap of CollPlant? | CollPlant's current market cap is $6M. |
| What is the current revenue of CollPlant? | CollPlant's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of CollPlant? | Current revenue multiple of CollPlant is 1.8x. |
| Is CollPlant profitable? | No, CollPlant is not profitable. |
| How many companies CollPlant has acquired to date? | CollPlant hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies CollPlant has invested to date? | CollPlant hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to CollPlant
Lists including CollPlant
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.